Skip to main content

Table 4 Comparison of three AKI biomarker study characteristics

From: Urinary cell cycle arrest biomarkers and chitinase 3-like protein 1 (CHI3L1) to detect acute kidney injury in the critically ill: a post hoc laboratory analysis on the FINNAKI cohort

 Sapphire [5]BAKI-I [8]FINNAKI-CHI3L1 (present study)
n728181660
Biomarker studiedTIMP-2•IGFBP7CHI3L1CHI3L1
TIMP-2•IGFBP7
CentersMultiSingleMulti
Age (years)64 (53, 73)60 (51, 70)64 (53, 73)
Male gender (%)626362
Baseline Cr (μmol/L)805882
Diabetes (%)297.221.2
SAPS IINANA38 (29, 49)
APACHE III69 (51, 90)NANA
SOFANA9 (7, 11)7 (4,9)
Emergency departmentNA41.4%41.2%
Medical ICU admission (%)31.059.770.9
AKI stages 2–3 < 12 h (%)14.03.3NA
AKI stages 2–3 < 24 h (%)NA4.97.4
AUC-ROC for AKI stages 2–3 < 12 h0.800.79NA
AUC-ROC for AKI stages 2–3 < 24 hNA0.72uCHI3L1, 0.67
NephroCheck, 0.67